Discrete choice experiment to investigate preferences for incentives to promote antimicrobial research and development
ABSTRACT: Objectives: Without intervention, experts predict that antimicrobial resistance will rank among leading drivers of mortality by 2050. New drugs are desperately needed, but given the lengthy development timelines for antimicrobial research and development (R&D), existing economic incen...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-06-01
|
| Series: | Journal of Global Antimicrobial Resistance |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213716522000418 |
| _version_ | 1817968050942509056 |
|---|---|
| author | Leon Rohde Elias Mossialos Charlotte Beaudart Angelika Joos Inka Heikkinen Silas Holland Mickaël Hiligsmann |
| author_facet | Leon Rohde Elias Mossialos Charlotte Beaudart Angelika Joos Inka Heikkinen Silas Holland Mickaël Hiligsmann |
| author_sort | Leon Rohde |
| collection | DOAJ |
| description | ABSTRACT: Objectives: Without intervention, experts predict that antimicrobial resistance will rank among leading drivers of mortality by 2050. New drugs are desperately needed, but given the lengthy development timelines for antimicrobial research and development (R&D), existing economic incentives fail to support a robust pipeline of new products. This study aims to elicit the preferences of stakeholders for adequate antimicrobial R&D incentive programs. Methods: A discrete choice experiment was conducted in which stakeholders (representatives from small or medium and large pharmaceutical companies, academics, clinicians, and policy makers) were asked in 12 choice tasks to select their preferred incentive combinations among two hypothetical options, differing in five attributes: form of monetary incentive, total amount of monetary incentive, market exclusivity extensions, transferable exclusivity extensions vouchers, and priority review vouchers. A subgroup analysis comprising only participants from the pharmaceutical industry was also conducted. Results: A total of 50 stakeholders (including 24 from the pharmaceutical industry) completed the survey in full. Participants preferred longer transferable exclusivity extensions and larger amounts of monetary rewards. The levels that were perceived as having the highest utility were $1 billion as total amount of incentives and transferable exclusivity extension for 18 months. The subgroup analysis provided similar findings. Conclusion: This study suggests that survey participants viewed transferable exclusivity vouchers for an 18-mo term and higher ($1 billion) monetary rewards as the preferred incentives to promote antimicrobial R&D. Further work is needed to design specific incentives and ensure they are implemented effectively. |
| first_indexed | 2024-04-13T20:03:55Z |
| format | Article |
| id | doaj.art-53b0290b8f85414790f3513cb19b1579 |
| institution | Directory Open Access Journal |
| issn | 2213-7165 |
| language | English |
| last_indexed | 2024-04-13T20:03:55Z |
| publishDate | 2022-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Global Antimicrobial Resistance |
| spelling | doaj.art-53b0290b8f85414790f3513cb19b15792022-12-22T02:32:07ZengElsevierJournal of Global Antimicrobial Resistance2213-71652022-06-01294248Discrete choice experiment to investigate preferences for incentives to promote antimicrobial research and developmentLeon Rohde0Elias Mossialos1Charlotte Beaudart2Angelika Joos3Inka Heikkinen4Silas Holland5Mickaël Hiligsmann6Healthcare Policy, Innovation and Management, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands; Corresponding author. Healthcare Policy, Innovation and Management, Faculty of Health, Medicine and Life Sciences, Maastricht University, Duboisdomein 30, 6229 GT Maastricht, NetherlandsLSE Health, London School of Economics and Political Science, London, United KingdomDepartment of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, NetherlandsGlobal Regulatory Policy, MSD, Brussels, BelgiumHealth Economics and Pharmacoeconomics, Global Regulatory Policy, MSD, Copenhagen, DenmarkGlobal Public Policy, MSD, Washington D.C., USADepartment of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, NetherlandsABSTRACT: Objectives: Without intervention, experts predict that antimicrobial resistance will rank among leading drivers of mortality by 2050. New drugs are desperately needed, but given the lengthy development timelines for antimicrobial research and development (R&D), existing economic incentives fail to support a robust pipeline of new products. This study aims to elicit the preferences of stakeholders for adequate antimicrobial R&D incentive programs. Methods: A discrete choice experiment was conducted in which stakeholders (representatives from small or medium and large pharmaceutical companies, academics, clinicians, and policy makers) were asked in 12 choice tasks to select their preferred incentive combinations among two hypothetical options, differing in five attributes: form of monetary incentive, total amount of monetary incentive, market exclusivity extensions, transferable exclusivity extensions vouchers, and priority review vouchers. A subgroup analysis comprising only participants from the pharmaceutical industry was also conducted. Results: A total of 50 stakeholders (including 24 from the pharmaceutical industry) completed the survey in full. Participants preferred longer transferable exclusivity extensions and larger amounts of monetary rewards. The levels that were perceived as having the highest utility were $1 billion as total amount of incentives and transferable exclusivity extension for 18 months. The subgroup analysis provided similar findings. Conclusion: This study suggests that survey participants viewed transferable exclusivity vouchers for an 18-mo term and higher ($1 billion) monetary rewards as the preferred incentives to promote antimicrobial R&D. Further work is needed to design specific incentives and ensure they are implemented effectively.http://www.sciencedirect.com/science/article/pii/S2213716522000418Discrete choice experimentAntimicrobial resistanceAntibioticsPreference researchR&D incentives |
| spellingShingle | Leon Rohde Elias Mossialos Charlotte Beaudart Angelika Joos Inka Heikkinen Silas Holland Mickaël Hiligsmann Discrete choice experiment to investigate preferences for incentives to promote antimicrobial research and development Journal of Global Antimicrobial Resistance Discrete choice experiment Antimicrobial resistance Antibiotics Preference research R&D incentives |
| title | Discrete choice experiment to investigate preferences for incentives to promote antimicrobial research and development |
| title_full | Discrete choice experiment to investigate preferences for incentives to promote antimicrobial research and development |
| title_fullStr | Discrete choice experiment to investigate preferences for incentives to promote antimicrobial research and development |
| title_full_unstemmed | Discrete choice experiment to investigate preferences for incentives to promote antimicrobial research and development |
| title_short | Discrete choice experiment to investigate preferences for incentives to promote antimicrobial research and development |
| title_sort | discrete choice experiment to investigate preferences for incentives to promote antimicrobial research and development |
| topic | Discrete choice experiment Antimicrobial resistance Antibiotics Preference research R&D incentives |
| url | http://www.sciencedirect.com/science/article/pii/S2213716522000418 |
| work_keys_str_mv | AT leonrohde discretechoiceexperimenttoinvestigatepreferencesforincentivestopromoteantimicrobialresearchanddevelopment AT eliasmossialos discretechoiceexperimenttoinvestigatepreferencesforincentivestopromoteantimicrobialresearchanddevelopment AT charlottebeaudart discretechoiceexperimenttoinvestigatepreferencesforincentivestopromoteantimicrobialresearchanddevelopment AT angelikajoos discretechoiceexperimenttoinvestigatepreferencesforincentivestopromoteantimicrobialresearchanddevelopment AT inkaheikkinen discretechoiceexperimenttoinvestigatepreferencesforincentivestopromoteantimicrobialresearchanddevelopment AT silasholland discretechoiceexperimenttoinvestigatepreferencesforincentivestopromoteantimicrobialresearchanddevelopment AT mickaelhiligsmann discretechoiceexperimenttoinvestigatepreferencesforincentivestopromoteantimicrobialresearchanddevelopment |